论文部分内容阅读
目的:探讨稳心颗粒治疗冠心病并频发室早的疗效及安全性。方法:40例冠心病并频发室早患者,随机分为两组,治疗组(稳心颗粒+冠心病药物治疗+β受体阻滞剂)和对照组(冠心病药物治疗+β受体阻滞剂),每组20例。于治疗前及治疗4 w后查心电图、24 h动态心电图及临床症状变化。结果:治疗组治疗4 w后室性早搏次数减少及症状缓解明显优于对照组,差异有统计学意义(P<0.05)。结论:稳心颗粒能有效减少冠心病并频发室早次数及减轻临床症状。
Objective: To investigate the efficacy and safety of Wenxin Granule in treating coronary heart disease (CHD) and frequent occurrence of CHD. Methods: Forty patients with coronary heart disease and frequent ventricular arrhythmia were randomly divided into two groups: treatment group (Wenxin Granule plus coronary artery disease plus beta-blocker) and control group (coronary heart disease plus beta-receptor Blockers), 20 cases in each group. Before treatment and 4 w after treatment check electrocardiogram, 24 h dynamic electrocardiogram and clinical symptoms. Results: After 4 weeks of treatment, the number of premature ventricular contractions and the relief of symptoms in the treatment group were significantly better than those in the control group (P <0.05). Conclusion: Wenxin Granule can effectively reduce coronary heart disease and frequent occurrence of coronary heart disease and relieve clinical symptoms.